Method for predicting the risk of death in patients with cardiorenal syndrome type 2 and heart failure with intermediate and reduced ejection fraction

The invention relates to medicine, in particular to cardiology and nephrology.Summary of the invention consists in that it is conducted the clinical and paraclinical examination, where is determined the serum level of cystatin C (CYS) and the level of hemoglobin (HB), is estimated the glomerular filtration rate using a simplified formula based on cystatin C (RFG100/cys), is determined the severity of the heart failure (IC), is conducted the echocardiographic study with the assessment of left ventricular dysfunction, is determined the degree of patient mobility (MOB), the duration of cardiovascular disease (DBCV) and the presence of emotional stress (STRESS), and the discriminant function (F) is calculated by the formula:F = - 0.552 - 0.601 · RFG100/cys - 0.633 · STRESS + 1.921 · MOB + 1,450 · CYS - 0.054 · DBCV - 0.019 · HB + 0.503 · IC;in the case when F > 0 is predicted an increased risk of death, and F < 0 - a low risk of death. Invenţia se referă la medicină, în special la cardiologie şi nefrologie.Esenţa invenţiei constă în aceea că se efectuează examenul clinic şi paraclinic, unde se determină nivelul cistatinei C serice (CYS) şi nivelul hemoglobinei (HB), se estimează rata filtrării glomerulare utilizând formula simplă în baza cistatinei C (RFG100/cys), se determină severitatea insuficienţei cardiace (IC), se efectuează examenul ecocardiografic cu aprecierea disfuncţiei ventriculului stâng, se determină gradul de mobilitate a pacientului (MOB), durata bolii cardiovasculare (DBCV) şi prezenţa stresului emoţional (STRESS), iar funcţia discriminantă (F) se calculează conform formulei:F= - 0,552 - 0,601 · RFG100/cys - 0,633 · STRESS + 1,921 · MOB + 1,450 · CYS - 0,054 · DBCV - 0,019 · HB + 0,503 · IC;în cazul în care F > 0 se pronosticheaza un risc crescut de deces, iar F < 0 - un risc scăzut de deces. Изобретение относится к медицине, в частности к кардиологии и нефрологии.Сущность изобретения состоит в том, что проводят клиническое и параклиническое обследование, где определяют сывороточный уровень цистатина C (CYS) и уровень гемоглобина (HB), оценивают скорость клубочковой фильтрации с использованием упрощенной формулы на основе цистатина С (RFG100/cys), определяют тяжесть сердечной недостаточности (IC), выполняют эхокардиографическое исследование с оценкой дисфункции левого желудочка, определяют степень мобильности пациента (MOB), продолжительность сердечно-сосудистого заболевания (DBCV) и присутствие эмоционального стресса (STRESS), а дискриминантн